Q&A: Exploring the challenges behind oncology trials
Despite ongoing discussions surrounding their improvement, running oncology trials remains highly challenging in the clinical research space that suffers from…
All articles by Adam Zamecnik
Adam Zamecnik
@a_zamecnik
Adam Zamecnik is a healthcare reporter for Pharmaceutical Technology. He has covered diverse topics such as continuous drug manufacturing, genomic research and sexual health. He is particularly interested in new technologies, health inequality, and cell and gene therapy research.
-
-
Q&A: Tackling the rise of fake anti-obesity drugs on the market
In October, the European Medicines Agency (EMA) alerted both patients and regulators of reported cases of falsified Ozempic (semaglutide) pens…
-
CTO Europe 2023: A snapshot of challenges and opportunities in oncology
Global developments and old challenges clash with the arrival of new technologies for drug development in oncology, creating both opportunities…
-
CTO Europe 2023: EU’s IVD guidelines continue affecting early clinical work
The implementation of the In Vitro Diagnostic Medical Devices Regulation (IVDR) by the European Union (EU) continues to be a…
-
CTO Europe 2023: Fostering diverse oncology trials remains a challenge
Lacking diversity in clinical trials remains a challenge as 73% of global study participants are white, based on data presented…
-
CTO Europe 2023: Reflections on drug development through the phases
Precision medicine oncology trial designs improve the likelihood of a drug’s approval by 38%, based on a presentation held by…
-
CTO Europe 2023: Cancer clinical trials shift as sector goes digital
Building on the increased adoption of digital trial capabilities due to the Covid-19 pandemic, the future of clinical trials will…
-
How can smaller biotechs navigate the landscape of oncology trials?
The challenges and prospects of running oncology trials are set to be dissected at the upcoming 10th Annual Clinical Trials…
-
How gene therapies can transform sickle cell disease treatment
The treatment of sickle cell disease is set to transform with the upcoming US approval decisions for two gene therapies…
-
CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar
CymaBay Therapeutics could file for a regulatory approval of its primary biliary cholangitis drug seladelpar with the US Food and…